Sarepta Therapeutics Inc (SRPT)
109.11
-3.37
(-3.00%)
USD |
NASDAQ |
Nov 14, 16:00
109.08
-0.03
(-0.03%)
After-Hours: 20:00
Sarepta Therapeutics Net Income (TTM): 121.84M for Sept. 30, 2024
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 121.84M |
| June 30, 2024 | 47.30M |
| March 31, 2024 | 16.90M |
| December 31, 2023 | -535.98M |
| September 30, 2023 | -690.88M |
| June 30, 2023 | -907.68M |
| March 31, 2023 | -1.115B |
| December 31, 2022 | -703.49M |
| September 30, 2022 | -716.22M |
| June 30, 2022 | -506.63M |
| March 31, 2022 | -356.56M |
| December 31, 2021 | -418.78M |
| September 30, 2021 | -486.12M |
| June 30, 2021 | -634.47M |
| March 31, 2021 | -703.89M |
| December 31, 2020 | -554.13M |
| September 30, 2020 | -600.51M |
| June 30, 2020 | -530.34M |
| March 31, 2020 | -655.92M |
| December 31, 2019 | -715.08M |
| September 30, 2019 | -620.27M |
| June 30, 2019 | -570.33M |
| March 31, 2019 | -403.20M |
| December 31, 2018 | -361.92M |
| September 30, 2018 | -245.02M |
| Date | Value |
|---|---|
| June 30, 2018 | -216.36M |
| March 31, 2018 | -170.14M |
| December 31, 2017 | -50.69M |
| September 30, 2017 | -115.14M |
| June 30, 2017 | -124.15M |
| March 31, 2017 | -123.40M |
| December 31, 2016 | -267.26M |
| September 30, 2016 | -243.49M |
| June 30, 2016 | -238.69M |
| March 31, 2016 | -218.24M |
| December 31, 2015 | -220.03M |
| September 30, 2015 | -199.76M |
| June 30, 2015 | -177.05M |
| March 31, 2015 | -169.08M |
| December 31, 2014 | -135.79M |
| September 30, 2014 | -100.19M |
| June 30, 2014 | -113.00M |
| March 31, 2014 | -98.17M |
| December 31, 2013 | -111.98M |
| September 30, 2013 | -165.23M |
| June 30, 2013 | -172.76M |
| March 31, 2013 | -145.67M |
| December 31, 2012 | -121.29M |
| September 30, 2012 | -60.63M |
| June 30, 2012 | -15.10M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-1.115B
Minimum
Mar 2023
121.84M
Maximum
Sep 2024
-532.29M
Average
-577.32M
Median
Net Income (TTM) Benchmarks
| Catalyst Pharmaceuticals Inc | 142.80M |
| Vertex Pharmaceuticals Inc | -479.80M |
| Alnylam Pharmaceuticals Inc | -332.26M |
| Biomarin Pharmaceutical Inc | 322.29M |
| Cytokinetics Inc | -576.40M |